Literature DB >> 12210793

Progressive loss of cardiac sympathetic innervation in Parkinson's disease.

Sheng-Ting Li1, Raghuveer Dendi, Courtney Holmes, David S Goldstein.   

Abstract

This study addressed whether cardiac sympathetic denervation progresses over time in Parkinson's disease. In 9 patients without orthostatic hypotension, 6-[(18)F]fluorodopamine positron emission tomography scanning was repeated after a mean of 2 years from the first scan. 6-[(18)F]fluorodopamine-derived radioactivity was less in the second scan than in the first scan, by 31% in the left ventricular free wall and 16% in the septum. In Parkinson's disease, loss of cardiac sympathetic denervation progresses in a pattern of loss suggesting a dying-back mechanism.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12210793     DOI： 10.1002/ana.10236

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  27 in total

1.  Cardiac sympathetic neuroimaging in dementia with lewy bodies.

Authors:  David S Goldstein
Journal:  J Neuroimaging       Date:  2010-10-26       Impact factor: 2.486

2.  Comparison of I-123 MIBG planar imaging and SPECT for the detection of decreased heart uptake in Parkinson disease.

Authors:  Jin-Kyoung Oh; Eun-Kyoung Choi; In-Uk Song; Joong-Seok Kim; Yong-An Chung
Journal:  J Neural Transm (Vienna)       Date:  2015-05-24       Impact factor: 3.575

3.  Cardiocirculatory manifestations in Parkinson's disease patients without orthostatic hypotension.

Authors:  T Pérez; B Tijero; I Gabilondo; A Luna; V Llorens; K Berganzo; M Acera; A Gonzalez; A Sanchez-Ferro; E Lezcano; J J Zarranz; J C Gómez-Esteban
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

Review 4.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

5.  Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration.

Authors:  Jeanette M Metzger; Helen N Matsoff; Alexandra D Zinnen; Rachel A Fleddermann; Viktoriya Bondarenko; Heather A Simmons; Andres Mejia; Colleen F Moore; Marina E Emborg
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

6.  2-Year Natural Decline of Cardiac Sympathetic Innervation in Idiopathic Parkinson Disease Studied with 11C-Hydroxyephedrine PET.

Authors:  Ka Kit Wong; David M Raffel; Nicolaas I Bohnen; Gulcin Altinok; Sid Gilman; Kirk A Frey
Journal:  J Nucl Med       Date:  2016-08-18       Impact factor: 10.057

Review 7.  Dysautonomia in Parkinson disease.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

8.  Reduced striatal tyrosine hydroxylase in incidental Lewy body disease.

Authors:  Thomas Gerald Beach; Charles H Adler; Lucia I Sue; Jeffrey B Peirce; Jyothi Bachalakuri; Jessica E Dalsing-Hernandez; Lih Fen Lue; John N Caviness; Donald J Connor; Marwan N Sabbagh; Douglas G Walker
Journal:  Acta Neuropathol       Date:  2007-11-06       Impact factor: 17.088

9.  Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET.

Authors:  Ka Kit Wong; David M Raffel; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen; Sid Gilman
Journal:  Radiology       Date:  2012-07-27       Impact factor: 11.105

10.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.